We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
A year ago at the J.P. Morgan Healthcare Conference, new Teva CEO Kåre Schultz detailed his plan to get the struggling drugmaker back on track. In 2019, he reported that things were playing out as planned—partly thanks to a factor he “couldn’t predict” la
A year ago at the J.P. Morgan Healthcare Conference, new Teva CEO Kåre Schultz detailed his plan to get the struggling drugmaker back on track. In 2019, he reported that things were playing out as planned—partly thanks to a factor he “couldn’t predict” la